How Has the Cholestatic Pruritus Market Evolved Historically and What is its Current Size?
The cholestatic pruritus market has seen considerable growth due to a variety of factors.
• The market size for cholestatic pruritus has significantly expanded in the recent past. A leap is expected from its size of $19.20 billion in 2024 to $20.28 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 5.6%.
The surge in market size during the historical period is linked with an increase in skin condition cases, escalating research and development funding, the need for efficient treatments, heightened disease awareness, and conducive regulatory frameworks.
What Does Future Hold for The Cholestatic Pruritus Market in the Coming Years?
The cholestatic pruritus market is expected to maintain its strong growth trajectory in upcoming years.
• Strong expansion is anticipated in the cholestatic pruritus market in the coming years, with a forecasted growth to $24.97 billion by 2029, reflecting a compound annual growth rate (CAGR) of 5.3%.
The surge anticipated throughout this forecast period can be linked to factors such as the aging population, the rise in cases of atopic dermatitis and urticaria, an increase in the elderly demographic, a rise in chronic kidney diseases, and a growing incidence of pruritus-related conditions. Key trends forecasted for the period include the launch of new therapy options, collaborations with key businesses for research on cholestasis pruritus, innovation in treatment methods, expansion in healthcare infrastructure, and advancements in technology.
What Factors Are Driving Growth In The Cholestatic Pruritus Market?
The cholestatic pruritus market is predicted to expand due to the growing number of liver disease cases. These diseases broadly cover conditions affecting liver functionality, ranging from infections, autoimmune disorders, genetic diseases, to damages resulting from toxins, ultimately causing inflammation, scarring, or liver failure. Factors such as rising obesity rates, diabetes, alcohol consumption, viral hepatitis infections, and exposure to environmental toxins and elements contribute to the increasing prevalence of liver diseases. Cholestatic pruritus acts as a crucial symptom in identifying and managing liver diseases, signifying impaired bile flow and often necessitating further exploration and remedy for underlying hepatic conditions. For example, the Office for Health Improvement and Disparities, a government entity in the UK aimed at tackling health disparities, reported in July 2023 that hospital admissions due to liver disease in England escalated by 22% in the year ending 2022, climbing from 67,458 to 82,290. Consequently, the persistent rise in liver disease cases will stimulate the growth of the cholestatic pruritus market.
What Is The Segmentation Of The Global Cholestatic Pruritus Market?
The cholestatic pruritus market covered in this report is segmented –
1) By Disease Type: Primary Biliary Cholangitis (PBC), Primary Sclerosing Cholangitis (PSC), Intrahepatic Cholestasis of Pregnancy (ICP), Other Disease Types
2) By Treatment Type: Medications, Phototherapy, Other Treatment Types
3) By Route Of Administration: Oral, Topical, Injectable
4) By End-User: Hospitals, Clinics, Ambulatory Care Centers, Homecare
Subsegments:
1) By Primary Biliary Cholangitis (PBC): Early-Stage PBC, Advanced PBC, PBC With Cirrhosis, PBC With Liver Failure
2) By Primary Sclerosing Cholangitis (PSC): Classic PSC, PSC With Ulcerative Colitis, PSC With Bile Duct Strictures
3) By Intrahepatic Cholestasis of Pregnancy (ICP): Mild ICP, Severe ICP, ICP With Preterm Birth Risk
4) By Other Disease Types: Alcoholic Cholestasis, Drug-Induced Cholestasis, Viral Hepatitis-Induced Cholestasis, Genetic Cholestasis Disorders
Pre-Book The Cholestatic Pruritus Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
What Emerging Trends Are Shaping The Cholestatic Pruritus Market Landscape?
Leading businesses in the cholestatic pruritus market are devoting efforts into the creation of innovative solutions such as oral treatments aimed at managing symptoms more effectively, enhancing patient adherence, and delivering targeted relief by tackling the root causes like bile salt accumulation and inflammation. An oral solution created for cholestatic pruritus treatment is a liquid medication designed to decrease the accumulation of bile acid and relieve patients with cholestasis from intense itching. For example, Mirum Pharmaceuticals Inc., a biopharmaceutical company located in the U.S., was granted approval by the U.S. Food and Drug Administration (FDA) in March 2024 for their oral solution LIVMARLI (maralixibat) intended for the treatment of cholestatic pruritus in patients aged five and above with progressive familial intrahepatic cholestasis (PFIC). This ileal bile acid transporter inhibitor, which is administered orally on a daily basis, has been designated as a breakthrough therapy for PFIC type 2. LIVMARLI is expected to significantly impact patients with PFIC-related cholestatic pruritus, providing a crucial treatment solution for those with the rarest subtypes.
Who Are the Key Players In The Cholestatic Pruritus Market?
Major companies operating in the cholestatic pruritus market are:
• GlaxoSmithKline plc
• Takeda Pharmaceutical Company Limited
• Merck KGaA
• Regeneron Pharmaceuticals Inc.
• Bausch Health Companies Inc.. Incyte Corporation
• Ipsen Pharma
• Vanda Pharmaceuticals Inc.
• Medison Pharma Ltd.
• Mirum Pharmaceuticals Inc.
• Albireo Pharma Inc.
• Dipharma Francis S.r.l.
• Cara Therapeutics Inc.
• CANbridge Pharmaceuticals Inc.
• Escient Pharmaceuticals Inc.
• Tharimmune Inc.
• Vifor Fresenius Medical Care Renal Pharma
• CymaBay Therapeutics Inc.
• ICE Pharma Inc.
• Aquatic Remedies Private Limited.
What Are The Regional Insights Into The Cholestatic Pruritus Market?
North America was the largest region in the cholestatic pruritus market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cholestatic pruritus market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
